Meet the Management Team

Bruce was appointed as Chief Executive Officer, effective 13 November 2020. Prior to that he was one of two Chief Operating Officers. In this role he was responsible for the company’s discovery, clinical development, program management, CMC and business development functions related to Small Molecule Therapeutics.

An accountant by training, he has spent almost three decades working in the life sciences and pharmaceutical industry. He has more than  eighteen years’ experience with Liminal and has held a number of senior global positions across the organisation.

Prior to being appointed CEO he became COO in 2014, previously he was the Group CFO, a role he had held since 2008. Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance.

As well as being a chartered accountant, Bruce also brought to the role many years of experience in general management and operations. Prior to joining Liminal, Bruce worked as a senior director for CV Therapeutics, a NASDAQ listed biopharmaceutical company.

Bruce is a graduate of Heriot-Watt University where he gained a BA in Accountancy and Computer Science. He is a member of the Institute of Chartered Accountants of Scotland and a Fellow of the Institute of Directors. He is also Chair of Court at Heriot-Watt University and a Non-Executive Director and Chair of the Audit Committee of The Rosalind Franklin Institute and is former Deputy President of The Institute of Chartered Accountants of Scotland.

Bruce is based in the United Kingdom.

Marie is Chief Legal Officer, General Counsel & Secretary for the Liminal Group. Marie oversees the legal, compliance, intellectual property and corporate governance functions. Marie is also Corporate Secretary for Liminal.

Marie has been with Liminal since 2013 and held positions of Associate General Counsel and Senior Legal Counsel. Marie has over twenty years of experience in the life sciences and pharmaceutical industry with extensive experience in financing transactions, strategic licensing and partnering transactions as well as acquisitions, clinical trial agreements, distribution agreements, supply agreements and R&D collaborations. Marie is also the Chair of the Data Protection Committee and Disclosure Committee.

Prior to joining the Company, Marie served as Director, Legal Affairs at Jubilant DraxImage and Jubilant Hollister Stier and  as Legal Counsel at DRAXIS Health Inc., a publicly-traded company, prior to its acquisition by Jubilant Life Sciences Inc. Prior to joining DRAXIS Health Inc., Marie was Legal Counsel, Company Secretary and Local Ethics Representative at Rolls-Royce Canada Limited.

Marie graduated from the Université of Montreal with a Bachelor of Law (LLB) in 2000 and is a member of the Québec Bar. Marie also holds a Certificate Arts and Sciences from the Université of Montréal (1997).

Gary holds a Ph.D in organic chemistry from the University of Manchester Institute of Science and Technology.

Gary has extensive experience in leading research and development through to commercialisation. He previously served as Executive Vice President of Research and Development at Xenon Pharmaceuticals Inc., Senior Vice President of Research and Development of Genzyme Corporation and co-founded AnorMED Inc., eventually acquired by Genzyme. Gary previously served as a Director on the Board of Aquinox Pharmaceuticals and as a Managing Director at Five Corners Capital

Inc. and as a venture partner at Venture West Capital Management, a venture capital firm.